Huiqiang Wei

416 total citations
16 papers, 324 citations indexed

About

Huiqiang Wei is a scholar working on Molecular Biology, Cancer Research and Immunology. According to data from OpenAlex, Huiqiang Wei has authored 16 papers receiving a total of 324 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Molecular Biology, 5 papers in Cancer Research and 4 papers in Immunology. Recurrent topics in Huiqiang Wei's work include Natural product bioactivities and synthesis (3 papers), Ubiquitin and proteasome pathways (3 papers) and interferon and immune responses (2 papers). Huiqiang Wei is often cited by papers focused on Natural product bioactivities and synthesis (3 papers), Ubiquitin and proteasome pathways (3 papers) and interferon and immune responses (2 papers). Huiqiang Wei collaborates with scholars based in China, United States and Hong Kong. Huiqiang Wei's co-authors include Yuqing Duan, Yong Qin, Changfen Bi, Yiliang Li, Ying Zhao, Wenfeng Gou, Yiliang Li, Qiang Liu, Deguan Li and Wenbin Hou and has published in prestigious journals such as Molecules, Cancer Letters and European Journal of Medicinal Chemistry.

In The Last Decade

Huiqiang Wei

16 papers receiving 317 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Huiqiang Wei China 10 192 64 61 46 37 16 324
Dinglai Yu China 8 234 1.2× 63 1.0× 81 1.3× 40 0.9× 25 0.7× 11 387
Lirui Sun China 12 163 0.8× 74 1.2× 58 1.0× 30 0.7× 27 0.7× 20 396
Katerina Gioti Greece 11 149 0.8× 50 0.8× 39 0.6× 41 0.9× 25 0.7× 22 300
P.Y. Yu China 11 209 1.1× 57 0.9× 55 0.9× 41 0.9× 16 0.4× 18 415
Rui‐Hong Gong Hong Kong 9 167 0.9× 80 1.3× 49 0.8× 24 0.5× 49 1.3× 20 329
Laura Llorach-Parés Spain 10 205 1.1× 37 0.6× 47 0.8× 67 1.5× 28 0.8× 12 412
Jinrui Wei China 12 214 1.1× 92 1.4× 71 1.2× 41 0.9× 27 0.7× 32 400
Aníbal Miranda Spain 6 238 1.2× 84 1.3× 102 1.7× 38 0.8× 23 0.6× 8 389
Bryant Megna United States 9 152 0.8× 46 0.7× 84 1.4× 41 0.9× 35 0.9× 23 370

Countries citing papers authored by Huiqiang Wei

Since Specialization
Citations

This map shows the geographic impact of Huiqiang Wei's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Huiqiang Wei with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Huiqiang Wei more than expected).

Fields of papers citing papers by Huiqiang Wei

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Huiqiang Wei. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Huiqiang Wei. The network helps show where Huiqiang Wei may publish in the future.

Co-authorship network of co-authors of Huiqiang Wei

This figure shows the co-authorship network connecting the top 25 collaborators of Huiqiang Wei. A scholar is included among the top collaborators of Huiqiang Wei based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Huiqiang Wei. Huiqiang Wei is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Peng, Zhenyu, et al.. (2023). SREBP inhibitors: an updated patent review for 2008-present. Expert Opinion on Therapeutic Patents. 33(10). 669–680. 8 indexed citations
2.
Wei, Huiqiang, Wenfeng Gou, Jun Gao, et al.. (2022). Novel PHD2/HDACs hybrid inhibitors protect against cisplatin-induced acute kidney injury. European Journal of Medicinal Chemistry. 230. 114115–114115. 7 indexed citations
3.
Gou, Wenfeng, Xiaojun Yu, Shao‐Hua Wu, et al.. (2022). Targeted inhibition of acidic nucleoplasmic DNA-binding protein 1 enhances radiosensitivity of non-small cell lung cancer. Cancer Letters. 530. 100–109. 12 indexed citations
4.
Gou, Wenfeng, Na Luo, Hongying Wu, et al.. (2022). Ursolic Acid Derivative UA232 Promotes Tumor Cell Apoptosis by Inducing Endoplasmic Reticulum Stress and Lysosomal Dysfunction. International Journal of Biological Sciences. 18(6). 2639–2651. 18 indexed citations
5.
6.
Wei, Huiqiang, Jingcheng Yu, Wenfeng Gou, et al.. (2021). Discovery of novel triazole compounds as selective IL-1β releasement inhibitors. Bioorganic & Medicinal Chemistry Letters. 53. 128415–128415. 4 indexed citations
7.
Wei, Huiqiang, et al.. (2021). Discovery and radiosensitization research of ursolic acid derivatives as SENP1 inhibitors. European Journal of Medicinal Chemistry. 227. 113918–113918. 9 indexed citations
8.
Li, Jing, Ruiqin Wu, Mingo M. H. Yung, et al.. (2021). SENP1-mediated deSUMOylation of JAK2 regulates its kinase activity and platinum drug resistance. Cell Death and Disease. 12(4). 341–341. 24 indexed citations
9.
Wei, Huiqiang, et al.. (2021). Recent Progress in Small-Molecule Inhibitors for Critical Therapeutic Targets of Necroptosis. Future Medicinal Chemistry. 13(9). 817–837. 5 indexed citations
10.
Jia, Jianhua, Huiqiang Wei, Yuqing Duan, et al.. (2020). An Improved Synthesis of the Triethylene Glycol-Substituted 4-(N-Methyl-N-Boc-Amino)Styrylpyridine. ACS Omega. 5(31). 19446–19452. 2 indexed citations
11.
Gou, Wenfeng, Huiqiang Wei, Hongying Wu, et al.. (2020). Ursolic acid derivative UA232 evokes apoptosis of lung cancer cells induced by endoplasmic reticulum stress. Pharmaceutical Biology. 58(1). 707–715. 19 indexed citations
12.
Wei, Huiqiang, Yuqing Duan, Wenfeng Gou, et al.. (2019). Design, synthesis and biological evaluation of novel 4-anilinoquinazoline derivatives as hypoxia-selective EGFR and VEGFR-2 dual inhibitors. European Journal of Medicinal Chemistry. 181. 111552–111552. 46 indexed citations
13.
Duan, Yuqing, Huiqiang Wei, Changfen Bi, et al.. (2019). Acetyl-CoA carboxylase (ACC) as a therapeutic target for metabolic syndrome and recent developments in ACC1/2 inhibitors. Expert Opinion on Investigational Drugs. 28(10). 917–930. 117 indexed citations
14.
15.
Wei, Huiqiang, et al.. (2002). Effect of PYCNOGENOL® on the toxicity of heart, bone marrow and immune organs as induced by antitumor drugs. Phytomedicine. 9(5). 414–418. 15 indexed citations
16.
Wei, Huiqiang, et al.. (1997). [Protective action of corynoline, acetylcorynoline and protopine against experimental liver injury in mice].. PubMed. 32(5). 331–6. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Dinglai Yu Breakdown of academic impact, for papers by Lirui Sun Breakdown of academic impact, for papers by Katerina Gioti Breakdown of academic impact, for papers by P.Y. Yu Breakdown of academic impact, for papers by Rui‐Hong Gong Breakdown of academic impact, for papers by Laura Llorach-Parés Breakdown of academic impact, for papers by Jinrui Wei Breakdown of academic impact, for papers by Aníbal Miranda Breakdown of academic impact, for papers by Bryant Megna
Rankless by CCL
2026